In addition, we assessed whether TMPRSS4 promoter methylation status could serve as a biomarker in plasma and bronchoalveolar lavage (BAL) samples to differentiate between NSCLC patients and healthy controls. This evidence concerns the gene TMPRSS4 and non-small cell lung carcinoma.